Troglitazone: A review of its use in the management of type 2 diabetes mellitus

Drugs

Volumn 57, Issue 3, 1999, Pages 409-438

  Plosker, Greg L ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIVER ENZYME; METFORMIN; ORAL CONTRACEPTIVE AGENT; SULFONYLUREA; TERFENADINE; TRIACYLGLYCEROL; TROGLITAZONE;

ASTHENIA; BACKACHE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; HEADACHE; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIVER TOXICITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PATIENT MONITORING; PHARYNGITIS; REVIEW; RHINITIS; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; VERTIGO;

ADULT; AGED; ANIMALS; AREA UNDER CURVE; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GLUCOSE; GLYBURIDE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033022510     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957030-00014     Document Type: Review

References (159)

1. Spencer CM, Markham A. Troglitazone. Drugs 1997 Jul; 54: 89-101
2. Harris MI. Diabetes in America (2nd edition). NIH Publication No. 95-1468, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD), 1995
3. Cowie CC, Eberhardt MS, editors. Diabetes 1996 vital statistics. Alexandria (VA): American Diabetes Association, 1996. 1-102
4. Tan GH, Nelson RL. Pharmacologic treatment options for noninsulin-dependent diabetes mellitus. Mayo Clin Proc 1996 Aug; 71: 763-8
5. Songer TJ, Zimmet PZ. Epidemiology of type II diabetes. An International perspective. Pharmacoeconomics 1995; 8 Suppl. 1: 1-11
6. McKeigue PM, Marmot MG, Syndercombe-Court YD, et al. Diabetes, hyperinsulinaemia and coronary risk factors in Bangladeshis in east London. Br Heart J 1988; 60: 990-6
7. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996 Jan; 19 Suppl. 1: 54-61
8. O'Rahilly S. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997 Mar 29; 314: 955-9
9. Hodge AM, Dowse GK, Zimmet PZ, et al. Prevalence and secular trends in obesity in Pacific and Indian Ocean island populations. Obesity Research 1995; 3 Suppl. 2: 77s-87s
10. Bressler R, Johnson DG. Oral antidiabetic drug use in the elderly. Drugs Aging 1996 Dec; 9: 418-37
11. Kuehnle HF. New therapeutic agents for the treatment or NIDDM. Exp Clin Endocrinol Diabetes 1996; 104 (2):93-101
12. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996 Dec; 45: 1661-9
13. Francisco Jr GE, Brooks PJ. Diabetes mellitus. In: DiPiro JT et al., editors. Pharmacotherapy: a pathophysiologic approach. 2nd ed. Norwalk (CT): Appleton & Lange, 1993: 1121-45
14. Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med 1996 Jan 1; 124 (Pt 2): 123-6
15. Dean JD, Durrington PN. Treatment of dyslipoproteinaemia in diabetes mellitus. Diabetic Med 1996 Apr; 13: 297-312
16. Orchard TJ, Forrest KY-Z, Ellis D, et al. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157 (1851-1856)
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352: 837-53
18. UK Prospective Diabetes study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 Sep 12; 352: 854-65
19. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes VII: mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240: 37-42
20. Nathan DM. Some answers, more controversy, from UKPDS [commentary]. Lancet 1998 Sept 12; 352: 832-3
21. The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
22. Saltiel AR, Horikoshi H. Thiazolidinediones are novel insulinsensitizing agents. Curr Opin Endocrinol Diabetes 1995; 2: 341-7
23. Whitcomb RW, Saltiel AR. Thiazolidinediones. Expert Opin Invest Drug 1995 Dec; 4: 1299-309
24. Martin G, Schoonjans K, Staels B, et al. PPARy activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998; 137 Suppl: S75-80
25. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptory (PPARγ). J Biol Chem 1995; 270 (22): 12953-6
26. Berger J, Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated rcceptor-γ. binding and activation correlated with antidiabetic actions in db/db mice. Endocrinology 1996; 137 (10): 4189-95
27. Wilson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-8
28. Corrêa JCN, Hilsted J, Eckland D, et al. Investigation of twice or three times daily dose regimen of troglitazone, an insulin action enhancer, in patients with non insulin dependent diabetes mellitus. Eur J Clin Res 1997; 9: 151-65
29. Fonseca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 1998; 83: 3169-76
30. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996 Jun; 39: 701-9
31. Leutenegger M, Sacca L, Alderton C, et al. Double-masked, placebo-controlled, dose-ranging study of troglitazone 10 to 200 mg once daily in non-insulin-dependent diabetes mellitus. Curr Ther Res Clin Exp 1997 Jul; 58: 403-16
32. Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats [in English]. Diabetes 1988 Nov; 37: 1549-58
33. Fürnsinn C, Neschen S, Noe C, et al. Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro. Br J Pharmacol 1997 Dec; 122: 1367-74
34. Kreutter DK, Andrews KM, Gibbs EM, et al. Insulin-like activity of new antidiabetic agent CP68722 in 3T3-L1 adipocytes. Diabetes 1990; 39: 1414-9
35. Lee MK, Olefsky JM. Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 1995 Sep; 44: 1166-9
36. Okuno A, Ikeda K, Shiota M, et al. Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb. Metabolism 1997 Jun; 46: 716-21
37. Park KS, Ciaraldi TP, Abrams-Carter L, et al. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. J Clin Endocrinol Metab 1998 May; 83: 1636-43
38. Szalkowski D, White-Carrington S, Berger J, et al. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995 Apr; 136: 1474-81
39. Cominacini L, Garbin U, Pastorino AM, et al. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 1997 Feb; 40: 165-72
40. Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062-71
41. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyle inflammatory cytokines. Nature 1998 Jan 1; 391: 82-6
42. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93 (2): 241-52
43. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93 (2): 229-40
44. Inoue I, Katayama S, Takahashi K, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commum 1997; 235: 113A-6A
45. Miles PDG, Romeo OM, Higo K, et al. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997 Nov; 46: 1678-83
46. Cominacini L, Young MMR, Capriati A, et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia 1997 Oct; 40: 1211-8
47. Cominacini L, Garbin U, Fratta-Pasini A, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998 Jan; 47: 130-3
48. Tack CJJ, Smits P, Demacker PNM, et al. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998 May; 21: 796-9
49. Hwang S-J, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 4219-25
50. Fujiwara T, Okuno A, Yoshioka S, et al. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995 Apr; 44: 486-90
51. Horikoshi H, Fujiwara T, Yoshioka T, et al. Pharmacological characteristics of new antidiabetic agent CS-045 in diabetic animals. In: Shafrir E, editor. Frontiers in diabetes research. Lessons from animal diabetes III.: Smith-Gordon, 1990: 320-4
52. Inoue I, Takahashi K, Katayama S, et al. Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and β-oxidation in fructose-fed rats. Metabolism 1995 Dec; 44: 1626-30
53. Khoursheed M, Miles PD, Gao KM, et al. Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism 1995 Nov; 44: 1489-94
54. Lee M-K. Miles PDG, Khoursheed M, et al. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994 Dec; 43: 1435-9
55. Yagi N, Takasu N, Higa S, et al. Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance. Horm Metab Res 1995 Oct; 27: 439-41
56. Nagai T, Yasunami Y, Nagata N, et al. Amelioration of hyperglycemia in streptozotocin-induced diabetic rats receiving a marginal mass of islet grafts by troglitazone, an oral antidiabetic agent. Pancreas 1996; 13 (4): 381-7
57. Tominaga M, Igarashi M, Daimon M, et al. Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 1993 Jun; 40: 343-9
58. Fujiwara T, Wade M, Fukuda K, et al. Characterization of SC045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KSJ-db/db mice. Metabolism 1991; 40: 1213-8
59. Prigeon RL, Kahn SE, Porte JD. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998 Mar; 83: 819-23
60. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998 Mar 26; 338: 867-72
61. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 Feb 1; 128: 176-85
62. Suter SL, Nolan JJ, Wallace R et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992 Feb; 15: 193-203
63. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994 Nov 3; 331: 1188-93
64. Loi C-M, Young M, Randinitis E, et al. Clinical pharmacokinetics of troglitazone. Ann Arbor (MI): Department of Pharmacokinetics, Dynamics and Metabolism, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, 1999. (Data on file)
65. Parke-Davis. Rezulin (troglitazone) tablets. Prescribing information. Morris Plains, New Jersey, USA: Parke-Davis, 1997
66. Shibata H, Nii S, Kobayashi M, et al. Phase I study of a new hypoglycemic agcnt CS-045 in healthy volunteers. Safety and pharmacokinetics in single administration [in Japanese]. Rinsho Iyaku 1993; 9 (7): 1503-18
67. Young MA, Williams ZV, Eastmond R. Similar pharmacokinetics of troglitazone in young and elderly subjects [abstract]. Diabetologia 1996 Aug; 39 Suppl. 1: A233
68. Loi C-M, Randinitis EJ, Vassos AB, et al. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 1997 Dec; 37: 1114-20.
69. Kawai K, Kawasaki-Tokui Y, Odaka T, et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittel Forschung 1997 Apr; 47: 356-68
70. Shibukawa A, Sawada T, Nakao C, et al. High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma. J Chromatogr A 1995 Apr 21; 697: 337-43
71. Yamanouchi T, Shinohara T, Tagaya T, et al. Pharmacokinetics study of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus [in Japanese]. Rinsho Iyaku 1995; 11 (11): 2325-39
72. Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency. Eur J Clin Pharmacol 1998; 54: 567-71
73. Young MA, Lettis S, Eastmond R. Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food. Br J Clin Pharmacol 1998 Jan; 45: 31-5
74. Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996 Sep; 81: 3299-306
75. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997 Jul; 82: 2108-16
76. Izumino K, Sakamaki H, Ishibashi M, et al. Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. J Clin Endocrinol Metab 1997 Aug; 82: 2391-5
77. Takino H, Okuno S, Uotani S, et al. Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome. Diabetes Res Clin Pract 1994 Jul; 24: 167-72
78. Karam JH, Salber PR, Forsham PH. Pancreatic hormones & diabetes mellitus. In: Greenspan FS, editor. Basic and clinical endocrinology. 3rd ed. Morwalk (CT): Appleton & Lange, 1991: 592-650
79. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
80. Després J-P, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7
81. Hansen AP, Troglitazone Study Group. Effects of troglitazone, a thiazolidinedione, in elderly non-insulin-dependent diabetic patients [abstract]. Diabetologia 1995; 38 Suppl. 1: A200
82. Kumar S, Prange A, Schulze J, et al. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Diabetic Med 1998; 15: 772-9
83. Okamoto M, Okamoto M, Taniguchi T, et al. Efficacy of troglitazone in young and elderly patients with NIDDM [abstract]. Diabetes 1998 May; 47 Suppl. 1: A97
84. Claudi T, Starkie M, Frith L, et al. Troglitazone improves cardiovascular risk profile compared with glibenclamide [abstract]. Diabetic Med 1997; 14 Suppl. 4: 30
85. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997 Mar; 46: 433-9
86. Levin K, Thye-Rømn P, Foot E, et al. Metabolic effects of troglitazone in NIDDM patients [abstract]. Diabetes 1996 May; 45 Suppl. 2: 18A
87. Robinson ACJ, Gray RG, Bannister PA, et al. The effects of troglitazone on lipolysis, fatty acid mobilization, and glucose turnover in NIDDM [abstract]. Diabetic Med 1998; 15 Suppl. 1: S66
88. Rosinson ACJ, Gray RG, Bannister PA, et al. Troglitgazone (600 mg daily) reduces the rate of very low density synthesis and pool size in patients with NIDDM [abstract]. Diabetic Med 1998. 15 Suppl. 1: S29
89. Serrano-Rios M, Kler L, Frith L, et al. Troglitazone improves insulin resistance compared to metformin [abstract]. Diabetic Med 1997; 14 Suppl. 4: 22
90. Sironi AM, Vichi S, Gastaldelli A, et al. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997 Aug; 62: 194-202
91. Troglitazone Study Group. The metabolic effects of troglitazone in non-insulin dependent diabetes [abstract]. Diabetologia 1997 Jun; 40 Suppl. 1: 149A
92. Valiquett T, Balagtas C, Whitcomb R. Troglitazone dose-response study in patients with NIDDM [abstract]. Diabetes 1995 May; 44 Suppl. 1: 109A
93. Valiquett T, Huang S, Ghazzi M. Troglitazone monotherapy: long term efficacy in patients with type 2 diabetes [abstract]. Diabetes 1998; 47 Suppl. 1: A 17
94. Akanuma Y, Kosaka K, Kuzuya T. Long-term study of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 127-49
95. Akanuma Y, Kosaka K, Knzuya T, et al. Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with noninsulin dependent diabetes mellitus poorly controlled by diet alone. A dose-finding study by dose increasing method [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 19-37
96. Ikeda Y, Yamada H, Ohno M. Clinical evaluation of a new oral hypoglycemic drug, CS-045, in patients with obese non-insulin dependent diabetes mellitus [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 179-90
97. Iwamoto Y, Kuzuya T, Matsuda A, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991 Nov; 14: 1083-6
98. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996 Feb; 19: 151-6
99. Kuzuya T, Iwamoto Y, Kosaka K, et al. An early phase 11 clinical trial of a new oral hypoglycemic drug, CS-045, in patients with non-insulin dependent diabetes mellitus [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 3-18
100. Maruyama H, Hirose H, Shimada A, et al. Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulin dependent diabetes mellitus. Study with 100mg tablet [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 205-15
101. Mimura K, Umeda F, Hiramatsu S, et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med 1994 Aug-Sep; 11: 685-91
102. Nakano K, Yasuda T, Kitagawa Y, et al. Clinical evaluation of a new oral hypoglycemic drug, CS-045, on daily profile of blood glucose in patients with non-insulin dependent diabetes mellitus [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 151-64
103. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995 Mar; 8: 316-20
104. Yamada N, Akanuma Y, Murase T, et al. Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with noninsulin dependent diabetes mellitus accompanying hypertriglyceridemia [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 165-78
105. Young MA, Eckland DJA, Eastmond R. Establishing the dose response curve for metabolic control with troglitazonc, an insulin action enhancer, in type 2 diabetes patients. Ann Med 1998 Apr; 30: 206-12
106. Kuzuya T, Kosaka K, Akanuma Y, et al. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998; 41: 121-9
107. Draznin B, Driscoll J, Sievers J, et al. Troglitazone plus sulfonylurea combination: long term efficacy in patients with type 2 diabetes [abstract]. Diabetes 1998 May; 47 Suppl. 1: A85
108. Foot EA, Patel J, Williams ZV, et al. Improved metabolic control by addition of troglitazone to glibenclamide therapy in non-insulin-dependent diabetics [abstract]. Diabetologia 1995 Aug; 38 Suppl. 1: A44
109. Horton ES, Whitehous F, Ghazzi MN, et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998; 21 (9): 1462-9
110. Akanuma Y, Kosaka K, Kuzuya T, et al. Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with noninsulin dependent diabetes mellitus poorly controlled by sulfonylureas. A dose-finding study by dose increasing method [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 39-60
111. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic Med 1996 Apr; 13: 365-70
112. Seino Y, Ishida H, Kurahachi H, et al. Clinical evaluation of a new oral hypoglycemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled with sulfonylureas. Study with 100mg tablet [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 3: 191-203
113. Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998 Mar 26; 338: 861-6
114. Buse JB, Gumbiner B, Mathias NP, et al. Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 1998; 21: 1455-61
115. Fonseca V, Graveline J, Nissel J. Long term experience with troglitazone in combination with insulin in type 2 diabetes mellitus [abstract]. Diabetes 1998 May; 47 Suppl. 1: A90
116. Akanuma Y, Kosaka K, Toyoda T, et al. Clinical evaluation of a new oral hypoglycemic agent CS-045 in combination with insulin [abstract]. Diabetologia 1996 Aug; 39 Suppl. 1: A232
117. Fukuda T, Nakano O, Amano M, et al. A clinical study of a new hypoglycemic agent, troglitazone, in type 2 diabetes patients who are unsatisfactorily-controlled with insulin [in Japanese]. Rinsho Iyaku 1995; 11 (10): 2055-62
118. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989; 12: 464-74
119. Kjos SL, Peters RK, Xiang A, et al. Predicting future diabetes in Latino women with gestational diabetes. Utility of early postpartum glucose tolerance teting. Diabetes 1995; 44: 586-91
120. Yamada T, Aizawa T, Nagasawa Y, et al. Ten-year follow-up of Japanese overweight subjects with impaired glucose tolerance: identification of a diabetes-prone subpopulation. Intern Med 1992; 31: 877-84
121. Antonucci T, Whitcomb R, McLain R, et al. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997 Feb; 20: 188-93
122. Berkowitz K, Peters R, Kjos SL, et al. Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes 1996 Nov; 45: 1572-9
123. Driscoll J, Ghazzi M, Perez J, et al. A 96-week follow-up on cardiac safety in patients with type II diabetes treated with troglitazone [abstract]. Diabetes 1997 May; 46 Suppl. 1: 149A
124. Diabetes Drug Pulled Back in UK [online]. Available from: URL: http://www.newspage.com/cgi-bin/pnp [Accessed 1997 Dec 4]
125. Glaxo Wellcome suspends troglitazone availability. Marketletter 1997 Dec 8; 24: 21
126. Warner Lambert Press Releases. Response of Parke-Davis to public citizen health research group's petition regarding rezulin (troglitazone) tablets. Available from URL: http://www.warner-lambert.com/rezulin.html [Accessed 1999 Jan 13]
127. FDA Talk Paper [online]. Available from: URL:http:// www.fda.gov/bbs/topics/ANSWERS/ANS00831.html [Accessed 1997 Nov 7]
128. Liver damage warnings for troglitazone. Scrip 1997 Nov 7 (2282): 21
129. FDA warns about diabetes drug [online]. Available from: URL: http://www.newspage.com/cgi-bin/pnp [Accessed 1997 Dec 4]
130. Rezulin under renewed fire as label changes. Marketletter 1998 Aug 3; 25: 19
131. Kuramoto K, Shimizu N, Toda G. Liver dysfunction associated with troglitazone (Noscal) [in Japanese]. Rinsho Iyaku 1998; 14 (3): 461-6
132. Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone [letter]. Ann Intern Med 1998; 129 (12): 1080
133. Warner-Lambert Rezulin arm in NIH diabetes prevention trial is being retained; Glaxo troglitazone withdrawal in U.K. prompts re-evaluation of U.S. status. FDC Pink 1997 Dec 8; 59: 5-6
134. Call to ban troglitazone in US. Scrip 1998 Jul 31 (2357): 22
135. Rezulin monitoring program to he watched closely at FDA Woodcock. Pink Sheet 1999 Jan 4; 61 (1): 14-5
136. Kaplan B, Friedman G, Jacobs M, et al. Potential interaction of troglitazone and cyclosporine. Transplantation 1998 May 27; 65: 1399-400
137. Loi C-M, Knowlton PW, Stern R, et al. Effect of troglitazone on steady-state pharmacokinetics of digoxin. J Clin Pharmacol 1998 Feb; 38: 178-83
138. Burgess SJ, Singer GG, Brennan DC. Effect of troglitazone on cyclosporine whole blood levels. Transplantation 1998 Jul 27; 66: 272
139. Frantz RP. Rezulin (troglitazone) greatly increases cyclosporine metabolism [letter]. J Heart Lung Transplant 1998; 17 (10): 1037-8
140. Park MH, Pelegrin D, Haug III MT, et al. Troglitazone, a new antidiabetic agent, decreases cyclosporine level [letter]. J Heart Lung Transplant 1998; 17 (11): 1139-40
141. Püchler K, Sasahara K, Witte PU, et al. Lack of pharmacokinetic interaction between troglitazone and glibenclamide in NIDDM patients [abstract]. Diabetologia 1996 Aug; 39 Suppl. 1: A232
142. Plowman BK, Morreale AP. Possible troglitazone-warfarin interaction. Am J Health System Pharm 1998 May 15; 55: 1071
143. Foot EA, Eastmond R. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects. Diabetes Res Clin Pract 1997 Oct; 38: 41-51
144. Young MA, Lettis S, Eastmond R. Concomitant administration of cholestyramine influences the absorption of troglitazone. Br J Clin Pharmacol 1998 Jan; 45: 37-40
145. Young MA, Lettis S, Eastmond R. Coadministration of acetaminophen and troglitazone: pharmacokinetics and safety. J Clin Pharmacol 1998; 38: 819-24
146. Koup JR, Anderson G, Loi CM. Effect or troglitazone on urinary excretion of cortisol and 6-β-hydroxycortisol. J Clin Pharmacol 1998; 38: 815-8
147. Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6-β-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction. J Pharm Sci 1995; 84: 292-4
148. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6-beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989; 28: 373-87
149. Lloyd AC, Williams Z, Lacey LA, et al. Impact of type II diabetes on employment status and work productivity [abstract no. 761]. Diabetologia 1996 Suppl. 1: A201
150. Warner DC, McCandless RR, De Nino LA, et al. Costs of diabetes in Texas, 1992. Diabetes Care 1996 Dec; 19: 1416-9
151. Troglitazone for non-insulin-dependent diabetes mellitus. Med Lett Drugs Ther 1997 May 23; 39:49-51
152. Petrie J, Small M, Connell J. Glitazones, a prospect for noninsulin-dependent diabetes. Lancet 1997 Jan 11; 349: 70-1
153. O'Shea SJ, Lloyd AC, Keech ML,et al. Costs of hypoglycaemia in type II diabetics treated with oral hypoglycaemic agents [abstract no. 871]. Diabetologia 1996 Suppl. 1: A230
154. Balfour JA, Clissold SP. Management or non-insulin-dependent diabetes mellitus: defining the role of melformin. Dis Manage Health Outcomes 1997 Jan; 1: 49-59
155. Johnson MD, Campbell LK, Campbell RK. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother 1998 Mar; 32: 337-48
156. Sartor G, Schertsten B, Carlstrom S, et al. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbuamide and diet regulation. Diabetes 1980; 29 (1): 41-9
157. Yoshioka K, Yokoo S, Yoshida T, et al. Is troglitazone a real indication for obese subjects with impaired glucose tolerance? [letter]. Diabetes Care 1997 Aug; 20: 1340-1
158. Whitcomb R. Is troglitazone a real indication for obese subjects with impaired glucose tolerance? Reply [letter]. Diabetes Care 1997 Aug; 20: 1341
159. US NIH halts Rezulin trial for diabetes prevention. Marketletter 1998 Jun 15; 25: 21